1212 International Journal of Stroke 18(10) Figure 1. Consort diagram of all patients. MSU: mobile stroke unit; EMS: emergency medical services; tPA: tissue plasminogen activator; PD: pre-existing disability; ND: no pre-existing disability; mRS: modified Rankin Scale. the MSU group was 0.42 ± 0.33 versus 0.36 ± 0.32 in the EMS group (p = 0.07). The adjusted linear regression for 90-day uw-mRS was not significantly different between MSU versus EMS (p = 0.42) in PD patients. The univariate and adjusted ordinal logistic analyses were also not different between the MSU and EMS groups (OR = 0.65, p = 0.07 and aOR = 0.67, p = 0.11, respectively) in PD patients. In the MSU group, 57% of PD patients returned to at least their baseline mRS versus 46% in the EMS group. The distribution of 90-day mRS for MSU versus EMS PD patients is presented in Figure 3. The 90-day uw-mRS for PD patients in the three baseline mRS subgroups is given in Table 2. The interaction between time to treatment (where time was considered as a binary variable) and PD versus ND for 90-day uw-mRS was not significant for either the unadjusted or adjusted linear regression (p = 0.17 and p = 0.18), or for the unadjusted and adjusted ordinal logistic regression (p = 0.84 and p = 0.98). International Journal of Stroke, 18(10) In both PD and ND groups, patients treated within the first " golden hour " after LKW had a better 90-day uw-mRS than those treated after this time frame (0.49 vs. 0.38 for PD patients and 0.81 vs. 0.78 for ND patients). The estimated coefficient (and 95% confidence interval (CI)) for the variable indicating treatment within the golden hour (compared to after the first hour) is 0.12 (0.03-0.22) for the PD patients, meaning that those treated within the golden hour had an average of 0.12 higher uw-mRS compared with those treated after the golden hour. The estimate (and 95% CI) is 0.06 (0.01-0.11) for the ND patients. The adjusted linear regression was significant for both groups (p = 0.01 and p = 0.02). Secondary outcomes sICH occurred in 2.4% of tPA-eligible PD patients versus 1.8% in ND. Mortality at 90 days was 23% in those with PD versus 6% in ND, and by 1 year was 37% versus 10%.